Survival and Toxicity Outcomes

Cross-source consensus on Survival and Toxicity Outcomes from 1 sources and 5 claims.

1 sources · 5 claims

Other

Highlighted claims

CTCAE grade 3 indicates severe toxicity requiring hospitalization or limiting self-care activities of daily living. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
Clinician-reported outcomes use CTCAE v5.0 to grade urinary, rectal, sexual, and fatigue-related toxicities. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
Survival outcomes include freedom from treatment failure at 5 years, cancer-specific survival, and overall survival. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
The trial anticipates PSA bounce within the first 2 years and will not classify it as treatment failure during that period. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer
Post-treatment imaging is left to the treating clinician rather than mandated by protocol. — The LDR BURST trial: a randomised controlled trial comparing the side effects of low-dose-rate brachytherapy against ultra-hypofractionated radiotherapy using spacer gel treatment in men with Cambridge Prognostic Groups 1–3 prostate cancer